CANAGLIFLOZIN, A NEW ANTI-DIABETIC AGENT TARGETING CELLULAR METABOLISM, SUPPRESSES SURVIVAL AND ENHANCES THE RESPONSE OF NON-SMALL CELL LUNG CANCER (NSCLC) TO RADIOTHERAPY Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Biziotis, Olga-Demetra
  • Tsakiridis, Evangelia-Evelyn
  • Broadfield, Lindsay
  • Farrell, Thomas
  • Menjolian, Gabe
  • Mathurin, Tammy
  • Mekhaeil, Bassem
  • Zacharidis, Panagiotis
  • Muti, Paola
  • Abdulkarim, Bassam
  • Steinberg, Gregory
  • Tsakiridis, Theodoros

publication date

  • October 1, 2019